Pathological cardiac hypertrophy can progress to heart failure, a significant global health challenge.[45, 46] Although β‐adrenergic receptor blockers and renin‐angiotensin‐aldosterone system inhibitors offer some benefit, the incidence of heart failure following hypertrophy remains extensive.[47] Understanding the molecular mechanisms underlying cardiac hypertrophy is therefore essential for developing better therapeutic interventions. The gene discussed is REN; the disease is hypertrophy.